MedPath

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Phase 1
Terminated
Conditions
Neoplasms
Interventions
Registration Number
NCT02659631
Lead Sponsor
Pfizer
Brief Summary

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
28
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PF-06671008PF-06671008-
Primary Outcome Measures
NameTimeMethod
Number of Participants With Dose-Limiting Toxicities (DLTs) - Part 1Baseline through Day 21 (Cycle 1)

DLT was defined as any of the following adverse events occurring in the first cycle of treatment (21 days after the first dose): a) Hematologic: Febrile neutropenia defined as an absolute neutrophil count (ANC) \<1.0 x 10\^9/L with a single temperature of \>38.3°C, or 101°F, or a sustained temperature of \>=38°C, or 100.4°F, for more than one hour; b) Non-hematologic: Delay by more than 2 weeks in receiving the next scheduled dose due to persisting treatment related toxicities; c) Any grade 3 or 4 clinically-relevant hematologic or non-hematologic toxicity.

Number of Participants With Objective Response (OR) - Part 2Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months

Number of participants with OR based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1.

CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions.

PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Secondary Outcome Measures
NameTimeMethod
Maximum Serum Concentration (Cmax) of PF-06671008C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Maximum serum concentration (Cmax) of PF-06671008 was observed directly from data.

Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06671008C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Tau refers to the dosing interval, which was 1 week. Area under the concentration-time profile from time 0 to time tau (AUCtau) was determined using linear/log trapezoidal method.

Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Number of Participants With Progression Free Survival (PFS) - Part 2Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression or unacceptable toxicity, or up to 24 months

The period from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-06671008C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Time for Maximum serum concentration (Tmax) of PF-06671008 was observed directly from data as time of first occurrence.

Number of Participants With OR - Part 1Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression, unacceptable toxicity, or up to 24 months

Number of participants with OR based on assessment of CR or PR according to RECIST v1.1.

CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions.

PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Terminal Elimination Half-life (t1/2) of PF-06671008C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Terminal elimination half-life (t1/2) of PF-06671008 was calculated as ln(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Arithmetic mean was not calculated if fewer than 3 participants had reportable parameter values.

Area Under the Curve From Time 0 Extrapolated to Infinity Time (AUCinf) of PF-06671008C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

AUCinf was calculated as AUClast +(Clast\*/kel), where AUClast is area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis, kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Systemic Clearance (CL) of PF-06671008C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Systemic Clearance (CL) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to IV arms.

Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Apparent Clearance (CL/F) of PF-06671008C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Apparent Clearance (CL/F) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to SC arm.

Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Number of Participants With Overall Survival (OS) - Part 2Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression or unacceptable toxicity, or up to 24 months

The period from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Number of Participants With Anti Drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF-06671008C1D1 0 hrs, D15 0 hrs, and C2D1 0 hrs, and D1 0 hrs post additional dosings, up to 24 months

ADA against PF-06671008 in human serum samples was determined following a tiered approach using screening, confirmation, and titer/quantification by semi-quantitative enzyme linked immunosorbent assay (ELISA). Endpoint titer \>=1.18 was considered positive.

Trial Locations

Locations (9)

Huntsman Cancer Hospital

🇺🇸

Salt Lake City, Utah, United States

Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion

🇺🇸

New York, New York, United States

Memorial Sloan Kettering Cancer Center- Clinical Trials Office

🇺🇸

New York, New York, United States

Memorial Sloan Kettering Cancer Center - Westchester

🇺🇸

Harrison, New York, United States

The University of Texas - M.D. Anderson Cancer Center

🇺🇸

Houston, Texas, United States

The University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Huntsman Cancer Institute

🇺🇸

Salt Lake City, Utah, United States

University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath